Exploring Genetic Risk Factors and Clinical Outcomes in Childhood Ocular Cancers

Daniel Tal^*
*Correspondence: Daniel Tal, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, Email:

Introduction

Childhood ocular cancers represent a rare but critical area of pediatric oncology. Understanding the genetic risk factors underlying these cancers is crucial for early detection, accurate diagnosis, and personalized treatment strategies. This article delves into the genetic landscape of childhood ocular cancers, exploring associated risk factors and their implications on clinical outcomes. The RB1 gene mutation is the most common genetic alteration associated with retinoblastoma, leading to loss of tumor suppressor function.

Description

Familial cases often exhibit germline mutations, while sporadic cases involve somatic mutations. The former presents with bilateral tumors and higher risk for secondary malignancies. Amplification of MYCN, MDM4, and DEK genes has been implicated in RB pathogenesis [1].

Trilateral retinoblastoma occurs in individuals with germline RB1 mutations, manifesting as synchronous or metachronous pinealoblastoma and retinoblastoma. Certain RB1 mutations predispose individuals to trilateral retinoblastoma, warranting vigilant surveillance. Ocular melanoma in children often harbors GNAQ or GNA11 mutations, distinct from adult cases. These benign tumors share genetic alterations with retinoblastoma, including RB1 mutations, albeit with less aggressive behavior [2].

Diagnosis and staging

Molecular genetic testing aids in confirming diagnosis, especially in cases with atypical clinical presentations or familial predisposition.

Imaging techniques such as ultrasound, MRI, and CT scans facilitate accurate staging, guiding treatment decisions.

Systemic chemotherapy, including vincristine, carboplatin, and etoposide, forms the backbone of retinoblastoma management, achieving tumor regression and preserving vision [3].

External beam radiation therapy or brachytherapy may be employed in cases refractory to chemotherapy or as adjuvant therapy post-surgery [4].

Surgical enucleation remains a primary treatment for advanced or refractory cases, ensuring complete tumor resection.

Survivors of childhood ocular cancers, particularly retinoblastoma, require lifelong surveillance due to increased risk of secondary malignancies, necessitating regular ophthalmologic and oncologic evaluations.

Genetic counseling and testing are integral for families with hereditary predisposition, facilitating informed decision-making regarding screening and risk-reducing measures [5].

Conclusion

Childhood ocular cancers encompass a spectrum of diseases with diverse genetic etiologies. Understanding the genetic risk factors not only aids in accurate diagnosis and risk stratification but also informs personalized treatment approaches and long-term surveillance strategies. Continued research into the genetic landscape of childhood ocular cancers holds promise for improving outcomes and quality of life for affected individuals.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Roy, Soma Rani and Fahmida Huque. "A review of childhood ocular, orbital, and surface tumors with updated clinical management."

Google Scholar, Crossref, Indexed at

2. Kivelä, Tero. "The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death." BJO 93 (2009): 1129-1131.

Google Scholar, Crossref, Indexed at

3. Shields, Jerry A. and Carol L. Shields. "Ocular tumors of childhood." Pediat Clin N 40 (1993): 805-826.

Google Scholar, Crossref, Indexed at

4. Rao, Ajay A., John H. Naheedy, James Y-Y. Chen and Shira L. Robbins, et al. "A clinical update and radiologic review of pediatric orbital and ocular tumors." Clin Oncol 2013 (2013).

Google Scholar, Crossref, Indexed at

5. Castillo, Bienvenido V and Lawrence Kaufman. "Pediatric tumors of the eye and orbit." Pediatr Clin North Am 50 (2003): 149-172.

Google Scholar, Crossref, Indexed at